Preclinical Program
Dengue Virus
Key Facts
About Biotron
Australian‑stage antivirals targeting viroporins to treat HIV, HCV and emerging viral diseases.
View full company profileAbout Biotron
Australian‑stage antivirals targeting viroporins to treat HIV, HCV and emerging viral diseases.
View full company profileAbout Biotron
Australian‑stage antivirals targeting viroporins to treat HIV, HCV and emerging viral diseases.
View full company profileAbout Biotron
Australian‑stage antivirals targeting viroporins to treat HIV, HCV and emerging viral diseases.
View full company profileAbout Excision BioTherapeutics
Excision BioTherapeutics is pioneering the application of CRISPR gene-editing technology to directly target and eliminate latent viral DNA from the human genome, focusing on large and complex viruses like HIV, HSV, and HBV. The company's lead program, EBT-101, is a first-in-human CRISPR-based therapy for HIV that has completed a Phase 1/2 trial, demonstrating initial safety and proof-of-concept. As a private, pre-revenue entity, Excision is advancing a pipeline of in vivo gene therapies with the potential to address significant unmet medical needs in virology and genetic diseases. Its strategy combines a novel therapeutic approach with a platform capable of targeting multiple indications.
View full company profileAbout Excision BioTherapeutics
Excision BioTherapeutics is pioneering the application of CRISPR gene-editing technology to directly target and eliminate latent viral DNA from the human genome, focusing on large and complex viruses like HIV, HSV, and HBV. The company's lead program, EBT-101, is a first-in-human CRISPR-based therapy for HIV that has completed a Phase 1/2 trial, demonstrating initial safety and proof-of-concept. As a private, pre-revenue entity, Excision is advancing a pipeline of in vivo gene therapies with the potential to address significant unmet medical needs in virology and genetic diseases. Its strategy combines a novel therapeutic approach with a platform capable of targeting multiple indications.
View full company profileAbout Excision BioTherapeutics
Excision BioTherapeutics is pioneering the application of CRISPR gene-editing technology to directly target and eliminate latent viral DNA from the human genome, focusing on large and complex viruses like HIV, HSV, and HBV. The company's lead program, EBT-101, is a first-in-human CRISPR-based therapy for HIV that has completed a Phase 1/2 trial, demonstrating initial safety and proof-of-concept. As a private, pre-revenue entity, Excision is advancing a pipeline of in vivo gene therapies with the potential to address significant unmet medical needs in virology and genetic diseases. Its strategy combines a novel therapeutic approach with a platform capable of targeting multiple indications.
View full company profileTherapeutic Areas
Other Dengue Virus Drugs
| Drug | Company | Phase |
|---|---|---|
| Broad-Spectrum Candidates | NanoViricides | Preclinical |